US’ Food and Drug Administration (FDA) is considering an accelerated approval for a drug to treat Alzheimer’s disease. Leqembi, developed by Biogen and Eisai, reduced marker of amyloid in Alzheimer’s patients’ brains and was associated with less decline in cognitive function than a placebo. The drug is currently being tested in a Phase 3 clinical…